#United States #New York #Pomerantz LLP #Valneva SE #Liability Claims

Pomerantz Law Firm Investigates Valneva SE Investors' Claims

In a noteworthy development for investors of Valneva SE, Pomerantz LLP has initiated an investigation concerning possible securities fraud perpetrated by the company and its executives. This announcement comes in light of recent events surrounding the clinical trial results of Valneva's Lyme disease vaccine candidate, an investigational drug developed in partnership with Pfizer Inc.

On March 23, 2026, Valneva, which trades on NASDAQ under the symbol VALN, alongside Pfizer, released topline results from a Phase 3 clinical trial known as VALOR, aimed at evaluating its six-valent vaccine for Lyme disease—designated PF-07307405 (formerly referred to as VLA15). While the companies presented the findings as positive, they simultaneously disclosed that the vaccine had not achieved its primary endpoint due to a reported low incidence of Lyme disease cases within the study population.

The unveiling of these disappointing results had immediate ramifications for Valneva's stock. Following the news, the price of Valneva’s American Depositary Receipt (ADR) plummeted by $3.83, equating to a staggering 37.11% drop and concluding the trading day at $6.49 per ADR. This sharp decrease undoubtedly heightened concerns among shareholders regarding the integrity of the company's communications and overall business practices.

The investigation led by Pomerantz LLP will delve deeper into whether Valneva and certain officers or directors engaged in misleading or illegal activities that could potentially have harmed investors. Individuals who have experienced losses related to their investments in Valneva are encouraged to contact Danielle Peyton of Pomerantz for further information on joining this class action investigation.

Pomerantz LLP stands as one of the foremost firms specializing in corporate and securities litigation. Founded by Abraham L. Pomerantz in the 1930s, the firm is recognized for its history of advocating for shareholders' rights and recovering substantial damages for victims of corporate malfeasance. As this investigation unfolds, it will be critical for affected investors to stay informed about the developments and explore their legal options.

For those interested in participating in this class action suit or seeking additional information, contact Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980.

As Pomerantz ramps up its inquiry, the ramifications for Valneva could be significant, affecting not only its future stock performance but also shaping investor confidence in the company moving forward. Stakeholders and observers alike will be watching carefully as this situation develops and as the firm, known for its advocacy in securities litigation, works to uncover the truth behind these serious allegations. The outcome of this investigation may set a precedent for how pharmaceutical companies communicate clinical trial results in the future, emphasizing the importance of transparency in the industry.

In conclusion, the implications of the Phase 3 trial results and the subsequent investigation by Pomerantz LLP serve as a reminder of the vigilance required in the complex world of investments, particularly in the volatile biotechnology sector. Investors should remain aware of their rights and be proactive in seeking justice when they believe they have been wronged in the marketplace.